Summary: Alkermes reported its Q2 2024 financial performance and advances in the development of narcolepsy treatments, particularly with the investigational drug ALKS 2680. The company highlighted its financial position, double-digit growth, and progress in its neuroscience … [Read more...]
Narcolepsy, Idiopathic Hypersomnia Study Reinforces Importance of Individualized Oxybates Dosing
By Sree Roy When starting people with narcolepsy and idiopathic hypersomnia on oxybates, sleep physicians know to individualize the treatment dosing based on each patient’s response as well as personal preference. A new study presented at SLEEP 2024 reinforces the importance of … [Read more...]
Orexin System-Based Drugs for Narcolepsy Are Coming
By Sree Roy Narcolepsy pharmacotherapies have existed in the US prescription drug market for decades. However none have targeted the orexin (hypocretin) system, even though it lies at the root of the neurological sleep disorder. But several biopharmaceutical companies are … [Read more...]
A Potential Fix Emerges for Narcolepsy Medication’s Palatability
By Sree Roy Ensuring a drug is absorbed as intended is certainly more important than the medicine’s palatability, but wouldn’t it be great to have both efficacy and a decent taste? For one narcolepsy drug, that conundrum was explored via a poster presentation at SLEEP 2024. … [Read more...]
Orexin-2 Receptor Agonist E2086 to Be Tested for Narcolepsy
Summary: Eisai Inc announced the registration and upcoming enrollment for Study E2086-A001-101, a clinical trial to evaluate the efficacy, safety, and tolerability of E2086, a novel selective orexin-2 receptor agonist, in adult patients with narcolepsy type 1. The trial, which … [Read more...]
FDA Rejects Petition Challenging Safety of Narcolepsy Drug Wakix
Summary: The FDA has denied a citizen petition filed by a short seller challenging the safety and effectiveness of Wakix (pitolisant) for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy. The FDA reaffirmed Wakix’s favorable benefit-risk profile and … [Read more...]
FDA Approves Non-Scheduled Narcolepsy Drug for Children
Summary: The FDA has expanded the approval of a narcolepsy drug, previously approved for adults, to now include children aged 6 and older. This new approval provides a non-scheduled treatment option for pediatric patients experiencing excessive daytime sleepiness due to … [Read more...]
Alkermes to Present Data for ALKS 2680 in Narcolepsy Treatment | Sleep Review
Summary: Alkermes plc introduced plans to present 3 posters at Rest 2024, showcasing the probable positive aspects of its investigational orexin 2 receptor agonist, ALKS 2680, for narcolepsy therapy. Displays will consist of information from a period 1b research, the layout of … [Read more...]
Mazindol Shows Neuroprotective Benefits in Narcolepsy Treatment
Summary: NLS Pharmaceutics Ltd will present a preclinical review at the ASCP convention exhibiting that mazindol, administered at 3 mg/kg, mitigated circadian exercise disruption in rats with narcoleptic-like indications induced by orexin-B-saporin lesions. The examine discovered … [Read more...]
Avadel to Present Data on Lumryz for Narcolepsy at SLEEP 2024
Summary: At Sleep 2024, Avadel will present new data on Lumryz, the initially extended-launch, when-nightly formulation of sodium oxybate for narcolepsy. Findings highlighted client preference for Lumryz around twice-nightly oxybate, with 94% preferring when-nightly dosing and … [Read more...]